Search
Research
A novel Fc-enhanced humanized monoclonal antibody targeting B7-H3 suppresses the growth of ESCCEsophageal squamous cell carcinoma (ESCC) is a prevalent malignant tumor of the digestive tract with a low 5-year survival rate due to the lack of effective treatment methods. Although therapeutic monoclonal antibodies (mAbs) now play an important role in cancer therapy, effective targeted mAbs are still lacking for ESCC.
Research
Editorial: Insights Into Biomarkers, Cytokines, and Chemokines in Skin CancerOur current Research Topic highlights the complexity of the relationship between the skin, immune system and skin cancer
Research
Dendritic cells and cancer: From biology to therapeutic interventionIn this review, we discuss the different subsets of tumor-infiltrating dendritic cells and their role in anti-tumor immunity
Research
Cross-presentation of cutaneous melanoma antigen by migratory XCR1+CD103− and XCR1+CD103+ dendritic cellsThis report provides new insight into the functional specialization within the broad network of dendritic cells that are responsible for skin immunosurveillance
Research
The Immune Response to Skin Trauma Is Dependent on the Etiology of Injury in a Mouse Model of Burn and Excision.This article investigates the impact of burn & excisional injury on the immune system.
Research
Renal Masses in Childhood: An Australian PerspectiveChildhood renal masses comprise a heterogeneous group of conditions that have a wide range of presentations. This review outlines an approach to the diagnostic work-up of childhood renal masses and discusses the most common presentations and treatments. Renal tumours make up 5% of childhood cancer in Australia, with Wilms tumour being the most common under age 10 years.
Research
T cells recognizing a 11mer influenza peptide complexed to H-2D b show promiscuity for peptide lengthT-cell repertoire is selected according to self peptide-MHC (major histocompatibility complex) complexes in the thymus.
Research
Prostaglandin E2 imprints a long-lasting effect on dendritic cell progenitors in the bone marrowInjection of BM-differentiated DCs from nonchimeric mice restored the reduced immune responses of PGE2-chimeric mice.
Research
Comprehensive Testing of Chemotherapy and Immune Checkpoint Blockade in Preclinical Cancer Models Identifies Additive CombinationsAntibodies that target immune checkpoints such as cytotoxic T lymphocyte antigen 4 (CTLA‐4) and the programmed cell death protein 1/ligand 1 (PD-1/PD-L1) are now a treatment option for multiple cancer types. However, as a monotherapy, objective responses only occur in a minority of patients. Chemotherapy is widely used in combination with immune checkpoint blockade (ICB). Although a variety of isolated immunostimulatory effects have been reported for several classes of chemotherapeutics, it is unclear which chemotherapeutics provide the most benefit when combined with ICB.
Research
Making a Killer: Selecting the Optimal Natural Killer Cells for Improved ImmunotherapiesOver the past 20 years natural killer (NK) cell-based immunotherapies have emerged as a safe and effective treatment option for patients with relapsed or refractory leukemia. Unlike T cell-based therapies, NK cells harbor an innate capacity to eliminate malignant cells without prior sensitization and can be adoptively transferred between individuals without the need for extensive HLA matching.